Leo Pharma developed and launched Dovobet (also known as Daivobet, Taclonex, Xamiol, and LEO-80185), a dermatological ointment formulation of the vitamin D analog calcipotriol and the corticosteroid betamethasone dipropionate, for the treatment of psoriasis.
Leo Pharma’s Dovobet (calcipotriol/betamethasone) franchise is the leading brand in the topical vitamin derivatives class, and has allowed the company to retain its leadership position within this class following the genericization of Dovonex (calcipotriol; Leo Pharma) and the withdrawal of Dovonex ointment from the market in early 2007. With patent protection until 2020, Datamonitor Healthcare expects Dovobet to maintain its leading position in the short-to-medium term.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Dovobet : Psoriasis
LIST OF FIGURES
8 Figure 1: Dovobet for psoriasis – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Dovobet in psoriasis
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Dovobet in psoriasis
LIST OF TABLES
4 Table 1: Dovobet drug profile
6 Table 2: Dovobet pivotal trial data in psoriasis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.